Cargando…

MiR-130a-3p Alleviates Inflammatory and Fibrotic Phases of Pulmonary Fibrosis Through Proinflammatory Factor TNF-α and Profibrogenic Receptor TGF-βRII

Pulmonary fibrosis (PF) is a progressive disease characterized by extracellular matrix (ECM) deposition that destroys the normal structure of the lung parenchyma, which is classified into two successive inflammatory and fibrotic phases. To investigate the anti-inflammatory and anti-fibrotic roles of...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Yan, Hou, Yapeng, Liu, Yanhong, Yu, Tong, Cui, Yong, Nie, Hongguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006815/
https://www.ncbi.nlm.nih.gov/pubmed/35431964
http://dx.doi.org/10.3389/fphar.2022.863646
_version_ 1784686739811467264
author Ding, Yan
Hou, Yapeng
Liu, Yanhong
Yu, Tong
Cui, Yong
Nie, Hongguang
author_facet Ding, Yan
Hou, Yapeng
Liu, Yanhong
Yu, Tong
Cui, Yong
Nie, Hongguang
author_sort Ding, Yan
collection PubMed
description Pulmonary fibrosis (PF) is a progressive disease characterized by extracellular matrix (ECM) deposition that destroys the normal structure of the lung parenchyma, which is classified into two successive inflammatory and fibrotic phases. To investigate the anti-inflammatory and anti-fibrotic roles of miR-130a-3p in mice with bleomycin (BLM)-induced PF and the underlying mechanism, we performed single-cell RNA-sequencing analysis, which demonstrated that BLM increased/decreased the percentage of macrophages and fibroblasts/epithelial cells in PF lungs, respectively. The differentially expressed genes were enriched in PPAR signaling pathway and lysosome, ECM–receptor interaction and ribosome, and metabolism reaction. Time-course studies demonstrated that the inflammation-related factors increased significantly at day 7 (inflammatory phase), whereas the fibrosis-related factors increased at day 28 (fibrotic phase) after BLM exposure. Meanwhile, miR-130a-3p could ameliorate pulmonary lesions by downregulating the secretion of inflammatory cytokines (IL-1β, IL-6, TNF-α, and TGF-β1) and the deposition of ECM (α-SMA, FN, HYP, and collagen) in the inflammatory and fibrotic phase, respectively. In the LPS-induced inflammatory cell model, the upregulation of miR-130a-3p was mainly achieved by the activation of the NF-κB signaling pathway, which suppressed the proinflammatory factor TNF-α. Comparatively, the TGF-β/Smad signaling pathway was inhibited by miR-130a-3p targeting TGF-βRII in the TGF-β1-deduced fibrotic cell model. The evidence supports that miR-130a-3p exerts an anti-inflammatory and anti-fibrotic effect in BLM-induced PF, implying a potential pharmacological agent in the therapy of PF patients.
format Online
Article
Text
id pubmed-9006815
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90068152022-04-14 MiR-130a-3p Alleviates Inflammatory and Fibrotic Phases of Pulmonary Fibrosis Through Proinflammatory Factor TNF-α and Profibrogenic Receptor TGF-βRII Ding, Yan Hou, Yapeng Liu, Yanhong Yu, Tong Cui, Yong Nie, Hongguang Front Pharmacol Pharmacology Pulmonary fibrosis (PF) is a progressive disease characterized by extracellular matrix (ECM) deposition that destroys the normal structure of the lung parenchyma, which is classified into two successive inflammatory and fibrotic phases. To investigate the anti-inflammatory and anti-fibrotic roles of miR-130a-3p in mice with bleomycin (BLM)-induced PF and the underlying mechanism, we performed single-cell RNA-sequencing analysis, which demonstrated that BLM increased/decreased the percentage of macrophages and fibroblasts/epithelial cells in PF lungs, respectively. The differentially expressed genes were enriched in PPAR signaling pathway and lysosome, ECM–receptor interaction and ribosome, and metabolism reaction. Time-course studies demonstrated that the inflammation-related factors increased significantly at day 7 (inflammatory phase), whereas the fibrosis-related factors increased at day 28 (fibrotic phase) after BLM exposure. Meanwhile, miR-130a-3p could ameliorate pulmonary lesions by downregulating the secretion of inflammatory cytokines (IL-1β, IL-6, TNF-α, and TGF-β1) and the deposition of ECM (α-SMA, FN, HYP, and collagen) in the inflammatory and fibrotic phase, respectively. In the LPS-induced inflammatory cell model, the upregulation of miR-130a-3p was mainly achieved by the activation of the NF-κB signaling pathway, which suppressed the proinflammatory factor TNF-α. Comparatively, the TGF-β/Smad signaling pathway was inhibited by miR-130a-3p targeting TGF-βRII in the TGF-β1-deduced fibrotic cell model. The evidence supports that miR-130a-3p exerts an anti-inflammatory and anti-fibrotic effect in BLM-induced PF, implying a potential pharmacological agent in the therapy of PF patients. Frontiers Media S.A. 2022-03-30 /pmc/articles/PMC9006815/ /pubmed/35431964 http://dx.doi.org/10.3389/fphar.2022.863646 Text en Copyright © 2022 Ding, Hou, Liu, Yu, Cui and Nie. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Ding, Yan
Hou, Yapeng
Liu, Yanhong
Yu, Tong
Cui, Yong
Nie, Hongguang
MiR-130a-3p Alleviates Inflammatory and Fibrotic Phases of Pulmonary Fibrosis Through Proinflammatory Factor TNF-α and Profibrogenic Receptor TGF-βRII
title MiR-130a-3p Alleviates Inflammatory and Fibrotic Phases of Pulmonary Fibrosis Through Proinflammatory Factor TNF-α and Profibrogenic Receptor TGF-βRII
title_full MiR-130a-3p Alleviates Inflammatory and Fibrotic Phases of Pulmonary Fibrosis Through Proinflammatory Factor TNF-α and Profibrogenic Receptor TGF-βRII
title_fullStr MiR-130a-3p Alleviates Inflammatory and Fibrotic Phases of Pulmonary Fibrosis Through Proinflammatory Factor TNF-α and Profibrogenic Receptor TGF-βRII
title_full_unstemmed MiR-130a-3p Alleviates Inflammatory and Fibrotic Phases of Pulmonary Fibrosis Through Proinflammatory Factor TNF-α and Profibrogenic Receptor TGF-βRII
title_short MiR-130a-3p Alleviates Inflammatory and Fibrotic Phases of Pulmonary Fibrosis Through Proinflammatory Factor TNF-α and Profibrogenic Receptor TGF-βRII
title_sort mir-130a-3p alleviates inflammatory and fibrotic phases of pulmonary fibrosis through proinflammatory factor tnf-α and profibrogenic receptor tgf-βrii
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006815/
https://www.ncbi.nlm.nih.gov/pubmed/35431964
http://dx.doi.org/10.3389/fphar.2022.863646
work_keys_str_mv AT dingyan mir130a3palleviatesinflammatoryandfibroticphasesofpulmonaryfibrosisthroughproinflammatoryfactortnfaandprofibrogenicreceptortgfbrii
AT houyapeng mir130a3palleviatesinflammatoryandfibroticphasesofpulmonaryfibrosisthroughproinflammatoryfactortnfaandprofibrogenicreceptortgfbrii
AT liuyanhong mir130a3palleviatesinflammatoryandfibroticphasesofpulmonaryfibrosisthroughproinflammatoryfactortnfaandprofibrogenicreceptortgfbrii
AT yutong mir130a3palleviatesinflammatoryandfibroticphasesofpulmonaryfibrosisthroughproinflammatoryfactortnfaandprofibrogenicreceptortgfbrii
AT cuiyong mir130a3palleviatesinflammatoryandfibroticphasesofpulmonaryfibrosisthroughproinflammatoryfactortnfaandprofibrogenicreceptortgfbrii
AT niehongguang mir130a3palleviatesinflammatoryandfibroticphasesofpulmonaryfibrosisthroughproinflammatoryfactortnfaandprofibrogenicreceptortgfbrii